ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
Inhibiting METTL3 in macrophages alleviates colitis by enhancing M2 polarization via upregulating IRAKM.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- mFrontiers in immunology · 2026Review
- Smad2/3 Regulates IL-6R m6A Methylation through METTL3 to Influence Inflammatory Responses in Hemorrhoidal Disease.Journal of innate immunity · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
OBJECTIVE AND
designN6-methyladenosine (m
methodsThe dextran sulfate sodium (DSS)-induced experimental colitis model was established. Conditional knockout of METTL3 in myeloid cells mice (Mettl3
resultsConditional knockout of Mettl3 in myeloid cells attenuated intestinal inflammation in experimental colitis. In vivo and in vitro studies confirmed that Mettl3 deletion skewed macrophages towards M2 activation. Mechanistically, Irakm, a negative regulator of TLR4 signaling, was identified as a target of METTL3-mediated m
conclusionOur study highlights the role of METTL3-IRAKM signaling in macrophage polarization and intestinal inflammation, providing a potential therapeutic target for the treatment of colitis.
Indexed as
Identifiers
41591461What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.